FDA's Peter Marks backs accelerated approval for gene therapies
Return of the megaround: is biotech back from the brink?
Selecta, Sobi rout gout in pair of phase 3 trials that could challenge Horizon
The rise, fall and future of Novavax
*please scroll down for all the latest news*
